BACKGROUND: Adalimumab is effective for moderate to severe chronic plaque psoriasis; however, data regarding retreatment following withdrawal and subsequent relapse are limited. OBJECTIVES: To evaluate the efficacy and safety of adalimumab if interrupted and then resumed in patients with moderate to severe psoriasis. METHODS: Patients in a long-term adalimumab open-label extension study (NCT00195676) who achieved a Physician's Global Assessment (PGA) score of 'Mild' (2), 'Minimal' (1) or 'Clear' (0) were withdrawn from adalimumab and monitored for relapse to PGA of 'Moderate' (3) or worse. The subgroup of interest had stable psoriasis control, defined as PGA of 0/1 for ≥12 weeks on every other week (eow) dosing before withdrawal. Relapsing patients were retreated with adalimumab (80 mg at week 0 and 40 mg eow starting at week 1). PGA, Psoriasis Area and Severity Index responses, fatigue, pharmacokinetics and immunogenicity were assessed. RESULTS: In total, 525 patients were withdrawn from adalimumab; the subgroup with stable psoriasis control comprised 285 patients. Of these, 178 relapsed (median=141 days) before treatment reinitiation and 107 did not relapse. Patients without relapse by 40 weeks off therapy reinitiated adalimumab. Rates of PGA 0/1 after 16 weeks of adalimumab retreatment were 89% for patients without relapse and 69% for patients who relapsed. Relapsers experienced significantly less fatigue after retreatment. Nine patients (3%) had serious adverse events (two were infections). No rebound or allergic reactions occurred. CONCLUSIONS: Adalimumab-treated patients who discontinued therapy and subsequently relapsed had a good likelihood of regaining clinical efficacy following adalimumab reinitiation.
BACKGROUND:Adalimumab is effective for moderate to severe chronic plaque psoriasis; however, data regarding retreatment following withdrawal and subsequent relapse are limited. OBJECTIVES: To evaluate the efficacy and safety of adalimumab if interrupted and then resumed in patients with moderate to severe psoriasis. METHODS:Patients in a long-term adalimumab open-label extension study (NCT00195676) who achieved a Physician's Global Assessment (PGA) score of 'Mild' (2), 'Minimal' (1) or 'Clear' (0) were withdrawn from adalimumab and monitored for relapse to PGA of 'Moderate' (3) or worse. The subgroup of interest had stable psoriasis control, defined as PGA of 0/1 for ≥12 weeks on every other week (eow) dosing before withdrawal. Relapsing patients were retreated with adalimumab (80 mg at week 0 and 40 mg eow starting at week 1). PGA, Psoriasis Area and Severity Index responses, fatigue, pharmacokinetics and immunogenicity were assessed. RESULTS: In total, 525 patients were withdrawn from adalimumab; the subgroup with stable psoriasis control comprised 285 patients. Of these, 178 relapsed (median=141 days) before treatment reinitiation and 107 did not relapse. Patients without relapse by 40 weeks off therapy reinitiated adalimumab. Rates of PGA 0/1 after 16 weeks of adalimumab retreatment were 89% for patients without relapse and 69% for patients who relapsed. Relapsers experienced significantly less fatigue after retreatment. Nine patients (3%) had serious adverse events (two were infections). No rebound or allergic reactions occurred. CONCLUSIONS:Adalimumab-treated patients who discontinued therapy and subsequently relapsed had a good likelihood of regaining clinical efficacy following adalimumab reinitiation.
Authors: William R Swindell; Xianying Xing; Philip E Stuart; Cynthia S Chen; Abhishek Aphale; Rajan P Nair; John J Voorhees; James T Elder; Andrew Johnston; Johann E Gudjonsson Journal: PLoS One Date: 2012-03-29 Impact factor: 3.240
Authors: Marie Masson Regnault; Jason Shourick; Fatma Jendoubi; Marie Tauber; Carle Paul Journal: Am J Clin Dermatol Date: 2022-04-30 Impact factor: 6.233
Authors: C E M Griffiths; R Vender; H Sofen; L Kircik; H Tan; S T Rottinghaus; M Bachinsky; L Mallbris; C Mamolo Journal: J Eur Acad Dermatol Venereol Date: 2016-09-07 Impact factor: 6.166